Q-omics provides the consensus-scored GRASLND profile across patient tissues and cancer cell-line models. GRASLND expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GRASLND is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, GRASLND RNA expression shows 16,655 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, HNSC, and UVM as cancer lineages where GRASLND shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRASLND — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRASLND survival associations across molecular data types. GRASLND RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRASLND RNA expression–survival associations across cancer types. High GRASLND expression shows unfavorable associations in KIRP, ACC, BLCA, LIHC, UVM and STAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for GRASLND RNA expression.
This table summarizes GRASLND tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for GRASLND. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRASLND shows higher tumor expression in HNSC, COAD, LUAD, BLCA, LUSC and BRCA. The HNSC box plot shows higher GRASLND RNA expression in tumor versus normal tissue (log2 FC = +1.040, t-test p < 0.001).
This table shows molecular features associated with GRASLND in patient tissues and cancer cell lines. In patient samples, GRASLND shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
